Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

Product description

Brivaracetam 10mg/ml Oral Solution
Reference Product: Briviact® / UCB
Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.
Dossier Status: On-going (EU CTD Available: Q4 2022)
Stability Studies: Zone II / Zone IVb
Shelf life (Originator): Four (4) years
Batch Size: To be defined
Pack Sizes: To be defined / Originator pack: BT x 1 Glass Bottle.
Read more

Specifications

Categories Pharmaceutical Products / ATC codingNervous System; Finished Dosage FormsOut-licensing
Sales markets Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia)
Supplied from Greece

More products from ANFARM HELLAS S.A.

View all our products (37)

Products from other suppliers

Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

Contact information

Address

Telephone

Website

View all contact information
Discover Innovation with Softigel by Procaps

Discover Innovation with Softigel by Procaps

Discover Japan’s premier contract manufacturing organization.

Discover Japan’s premier contract manufacturing organization.

Nanoform - an innovative nanoparticle medicine enabling company

Nanoform - an innovative nanoparticle medicine enabling company

Pfizer CentreOne

Pfizer CentreOne

AGC Pharma Chemicals Europe

AGC Pharma Chemicals Europe